The global psoriatic arthritis treatment market share was valued at USD 10.5 Billion in 2024. It is expected to grow to USD 23.2 Billion by 2033, exhibiting a CAGR of 8.71% during the forecast period from 2025 to 2033. Treatment options range from oral medications to biological therapies targeting immune system components with the goal of preventing disease progression, reducing pain, and preserving joint function. Physical therapy combined with these treatments helps strengthen muscles and enhance joint stability. 

Study Assumption Years

  • Base Year: 2024
  • Historical Years: 2019-2024
  • Forecast Period: 2025-2033

Psoriatic Arthritis Treatment Market Key Takeaways

  • Current Market Size: USD 10.5 Billion (2024)
  • CAGR: 8.71% (2025-2033)
  • Forecast Period: 2025-2033
  • Psoriatic arthritis is an autoimmune disorder causing joint inflammation.
  • Key players are developing treatments that prevent disease progression and protect joints while improving mobility.
  • Psoriasis is a major risk factor that influences market growth.
  • The disease most commonly affects adults aged 30 to 50, contributing to market growth.
  • Rising awareness of early diagnosis and treatment benefits is boosting demand.

Request Free Sample Report: https://www.imarcgroup.com/psoriatic-arthritis-treatment-market/requestsample

Market Growth Factors

Psoriasis disease is a key risk factor for development of psoriatic arthritis. Increasing psoriasis cases drive the market because of infections, stress, obesity, skin lesions, excessive alcohol consumption, and vitamin deficiency. Psoriasis and psoriatic arthritis are correlated to each other, which drives a worldwide demand for treatments.

Psoriatic arthritis affects people in the age range of 30 to 50 as the most common occurrence. This, along with the population that increases in the adult age group, is expected to grow the market during the period. Children with psoriatic arthritis can develop also uveitis, an inflammation of the uvea of the middle layer of the eye. This seems to be more common in people who have psoriatic arthritis and that has caused concern among parents of affected children.

Growing awareness of the benefits of early diagnosis and treatment to overcome pain and other damage to joints, and an increase in disposable income and healthcare infrastructure combined with awareness of new treatments to relieve the worst symptoms are driving growth.

Market Segmentation

IMARC Group segments the global psoriatic arthritis treatment market as follows:

  • Drug Type:
  • NSAIDs (Nonsteroidal Anti-Inflammatory drugs): Medications that reduce inflammation and pain.
  • DMARDs (Disease-Modifying Anti-Rheumatic Drugs): Drugs modifying disease progression.
  • Biologics: Therapies targeting specific components of the immune system.
  • Others: Additional types of treatments not classified above.
  • Type:
  • Prescription: Medications requiring a doctor's prescription.
  • OTC: Over-the-counter drugs available without prescription.
  • Route of Administration:
  • Injectable: Drugs administered via injections.
  • Oral: Medications taken by mouth.
  • Topical: Treatments applied directly on the skin.
  • Distribution Channel:
  • Hospital Pharmacies: Distribution through pharmacies located in hospitals.
  • Retail Pharmacies: Dispensing via retail drug stores.
  • Online Pharmacies: Internet-based pharmacy services.
  • Region:
  • North America: United States, Canada
  • Asia-Pacific: China, Japan, India, South Korea, Australia, Indonesia, Others
  • Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Others
  • Latin America: Brazil, Mexico, Others
  • Middle East and Africa

Regional Insights

North America is the largest regional market for the psoriatic arthritis treatment. The source does not explicitly state the market share or the CAGR of North America. However, it has large shares in other markets, such as in the United States and Canada.

Key Players

  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson Service ltd.
  • Novartis AG
  • Pfizer Inc.
  • Samsung Biologics
  • UCB S.A.

 

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302